3 results match your criteria: "Simcoderm Medical and Surgical Dermatology Centre[Affiliation]"
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
Arch Dermatol Res
June 2024
Division of Clinical Dermatology & Cutaneous Science, Department of Medicine, Halifax, Canada.
Secukinumab is a fully human IgG1 antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A. Secukinumab is an effective and well-tolerated treatment for plaque psoriasis. There is a limited real-word evidence for dose optimisation of secukinumab based on clinical response.
View Article and Find Full Text PDFSecukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Br J Dermatol
May 2024
Dermatology Centre, Hospital CUF Descobertas, Lisboa, Portugal.
Article Synopsis
- Hidradenitis suppurativa (HS) is a chronic skin condition, and secukinumab has shown sustained effectiveness and good safety for treating moderate-to-severe HS, though its performance in previously treated patients is unclear.
- The study analyzes data from two phase III trials (SUNSHINE and SUNRISE) to assess how prior exposure to biologics influences the efficacy and safety of secukinumab in HS patients.
- Results showed that secukinumab was more effective than placebo at 16 weeks for both biologic-experienced and biologic-naïve patients, indicating it remains a viable treatment option regardless of prior biologic treatment.
Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis.
JAAD Case Rep
March 2020
Simcoderm Medical and Surgical Dermatology Centre, Barrie, Ontario, Canada.